CareDx, Inc (CDNA) |
|
9.26 -0.16 (-1.7%)
|
03-22 12:40 |
|
Open: |
9.42 |
Pre. Close: |
9.42 |
|
High:
|
9.53 |
Low:
|
9.19 |
|
Volume:
|
264,003 |
Market Cap:
|
497(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 12:15:21 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 16.52 One year: 20.89 |
| Support: |
Support1: 8.1 Support2: 6.73 |
| Resistance: |
Resistance1: 14.15 Resistance2: 17.88 |
| Pivot: |
9.84  |
| Moving Average: |
MA(5): 9.38 MA(20): 11.19
MA(100): 13.51 MA(250): 19.78 |
| MACD: |
MACD(12,26): -1.4  Signal(9): -1.3 |
| Stochastic oscillator: |
%K(14,3): 14.1 %D(3): 13.4 |
| RSI: |
RSI(14): 35.1 |
| 52-week: |
High: 40.41 Low: 8.1 |
| Average Vol(K): |
3-Month: 1,439 (K) 10-Days: 1,222 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CDNA ] has closed above bottom band by 28.6%. Bollinger Bands are 53.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
9.63 - 9.69 |
9.69 - 9.75 |
|
Low:
|
9.01 - 9.07 |
9.07 - 9.14 |
|
Close:
|
9.32 - 9.42 |
9.42 - 9.51 |
|
Company Description |
|
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California. |
Headline News |
Mon, 13 Mar 2023
Gagnon Securities Now Owns 6.20% of CareDx (CDNA) - Nasdaq
Fri, 10 Mar 2023
CAREDX INVESTIGATION CONTINUED by Former Louisiana ... - Business Wire
Fri, 10 Mar 2023
CareDx, Inc (NASDAQ:CDNA) Q4 2022 Earnings Call Transcript - Yahoo Finance
Tue, 07 Mar 2023
Is CareDx Inc (CDNA) Stock a Smart Investment Tuesday? - InvestorsObserver
Tue, 07 Mar 2023
The American Society of Transplant Surgeons Position Statement ... - Business Wire
Mon, 06 Mar 2023
Loss-making CareDx (NASDAQ:CDNA) sheds a further US$308m, taking total shareholder losses to 72% over 1 year - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
54 (M) |
| Shares Float |
49 (M) |
|
% Held by Insiders
|
3.9 (%) |
|
% Held by Institutions
|
107 (%) |
|
Shares Short
|
4,880 (K) |
|
Shares Short P.Month
|
5,060 (K) |
Stock Financials |
|
EPS
|
-1.38 |
|
EPS Est Next Qtl
|
-0.18 |
|
EPS Est This Year
|
-0.82 |
|
EPS Est Next Year
|
-0.34 |
|
Book Value (p.s.)
|
8.05 |
|
Profit Margin (%)
|
-23.9 |
|
Operating Margin (%)
|
-24 |
|
Return on Assets (ttm)
|
-8.7 |
|
Return on Equity (ttm)
|
-17.1 |
|
Qtrly Rev. Growth
|
4 |
|
Gross Profit (p.s.)
|
3.9 |
|
Sales Per Share
|
5.99 |
|
EBITDA (p.s.)
|
-1.23 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-25 (M) |
|
Levered Free Cash Flow
|
-23 (M) |
Stock Valuations |
|
PE Ratio
|
-6.84 |
|
PEG Ratio
|
-0.8 |
|
Price to Book value
|
1.16 |
|
Price to Sales
|
1.56 |
|
Price to Cash Flow
|
-19.91 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
